BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Hosted on MSN1mon
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback